Meril Champions Innovation with Myval Octapro THV Launch at GISE 2024 & PCR LondonValves 2024

Meril, a global leader in cutting-edge cardiovascular and structural heart solutions, is renowned for its next-generation transcatheter heart valve technologies. Upholding its commitment to innovation, Meril continues to drive advancements in structural heart therapies, staying true to its mission of supporting patients and healthcare providers worldwide.

As part of this commitment, Meril is proud to announce the launch of its next-generation Myval Octapro THV, set to debut at the upcoming GISE 2024 and London Valves 2024 conferences. The Myval Octapro THV underscores Meril's dedication to redefining TAVR technology and shaping the future of structural heart care.

"At Meril, our commitment to developing and delivering state-of-the-art, best-in-class TAVR solutions remains unwavering. The trust the global clinical community has placed in the Myval THV series is a testament to its profound positive impact on patient outcomes, and we are dedicated to building on this legacy. With the launch of the Myval Octapro THV, doctors and patients worldwide will continue to benefit from Meril's advanced transcatheter heart valve portfolio," said Mr. Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences.

Explore in-depth details of the launch of Myval Octapro THV by Meril at the upcoming GISE 2024 and London Valves 2024 conferences. Access the complete article here:

https://bit.ly/49b2Me4